Insmed (INSM) Cost of Revenue (2018 - 2026)

Insmed has reported Cost of Revenue for 9 years, with the latest figure at $67.2 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 139.4% year-over-year to $67.2 million in Q2 2026; TTM through Jun 2026 was $188.2 million, a 94.69% increase from a year earlier, with the FY2025 full-year figure at $122.9 million, up 43.38% from the prior year.
• Cost of Revenue was $67.2 million for Q2 2026 at Insmed, up from $47.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $67.2 million in Q2 2026, with the low at $12.2 million in Q1 2022.
• Average Cost of Revenue over 5 years is $24.7 million, with a median of $19.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Cost of Revenue retreated 1.65% in 2022, then soared 139.4% in 2026.
• Over 5 years, Cost of Revenue stood at $13.1 million in 2022, then surged by 41.12% to $18.4 million in 2023, then surged by 41.79% to $26.2 million in 2024, then soared by 69.09% to $44.2 million in 2025, then soared by 51.99% to $67.2 million in 2026.
• The last three Cost of Revenue figures came in at $67.2 million (Q2 2026), $47.4 million (Q1 2026), and $44.2 million (Q4 2025), per Business Quant data.